DNA-hsp65Alternative Names: DNA-hsp65 cancer immunotherapy
Latest Information Update: 16 Jul 2016
At a glance
- Originator Farmacore
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Gene therapies; Immunotherapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Head and neck cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Head-and-neck-cancer in Brazil (Intratumoural, Injection)